In a patient with diabetic foot soft‑tissue infection caused by multidrug‑resistant Klebsiella pneumoniae that is only susceptible to gentamicin, amikacin, and tigecycline (tigecycline unavailable, and aztreonam unavailable for the ceftazidime/avibactam (Zavicefta) combination), should gentamicin be used as monotherapy?

Gentamicin Monotherapy Should NOT Be Used—Combination Therapy is Essential

In this scenario with MDR Klebsiella pneumoniae diabetic foot infection susceptible only to aminoglycosides (gentamicin, amikacin) and tigecycline (unavailable), you should use an aminoglycoside-containing combination regimen, NOT gentamicin monotherapy. The most appropriate approach is amikacin plus a second agent based on susceptibility testing, or if truly pan-resistant except to aminoglycosides, consider amikacin with high-dose meropenem (even if reported resistant) or fosfomycin if available.

Why Monotherapy Fails

Aminoglycoside monotherapy for serious soft tissue infections is inadequate for several critical reasons:

• Guideline-directed therapy mandates combination treatment for carbapenem-resistant Enterobacterales (CRE), which your MDR K. pneumoniae likely represents 1
• Tigecycline is specifically contraindicated for diabetic foot infections—the FDA label explicitly states it failed to demonstrate non-inferiority in clinical trials for DFIs and carries a black box warning for increased all-cause mortality 2
• Aminoglycosides have poor tissue penetration in diabetic foot soft tissue infections, particularly in ischemic or necrotic tissue, making monotherapy ineffective regardless of in vitro susceptibility 3

Recommended Treatment Algorithm

First-Line Approach:

Amikacin-based combination therapy (preferred over gentamicin due to better activity against MDR K. pneumoniae in Asian populations) 1:

1. Amikacin (15-20 mg/kg/day, with therapeutic drug monitoring) PLUS
2. High-dose meropenem (2g IV q8h as extended infusion over 3 hours) even if reported resistant—carbapenem "resistance" may be overcome with high doses in combination 1

Alternative if Meropenem Truly Fails:

• Amikacin PLUS fosfomycin IV (if available)—this combination has shown efficacy for CRE infections 1
• Amikacin PLUS colistin—though nephrotoxicity risk is substantial with dual nephrotoxic agents, this may be necessary for life/limb-threatening infection

Critical Adjunctive Measures:

• Aggressive surgical debridement is mandatory—the IWGDF/IDSA guidelines emphasize that antibiotic therapy alone is insufficient for infected diabetic foot ulcers 4
• Vascular assessment and revascularization if peripheral artery disease present
• Glycemic control optimization

Why Not Gentamicin Specifically?

While gentamicin is FDA-approved for serious infections including soft tissue 3, amikacin is superior for MDR K. pneumoniae because:

• K. pneumoniae isolates show significantly higher susceptibility to amikacin than gentamicin, particularly in regions with high MDR prevalence 1, 5
• Your organism being resistant to everything except aminoglycosides suggests extensive resistance mechanisms—amikacin is less affected by aminoglycoside-modifying enzymes common in MDR strains

Duration and Monitoring

• Treatment duration: 2-4 weeks for soft tissue DFI, depending on severity and presence of osteomyelitis 4
• Mandatory therapeutic drug monitoring for aminoglycosides to minimize nephrotoxicity and ototoxicity while ensuring adequate levels 1
• Avoid other nephrotoxic agents in the combination regimen 1
• Monitor renal function every 2-3 days during aminoglycoside therapy

The Ceftazidime-Avibactam Consideration

You mentioned aztreonam unavailability for the ceftazidime-avibactam (Zavicefta) combination. This is relevant because:

• Ceftazidime-avibactam PLUS aztreonam is the preferred regimen for metallo-beta-lactamase-producing K. pneumoniae (like NDM producers) 6, 7, 8
• If your isolate is truly only susceptible to aminoglycosides and tigecycline, it likely harbors multiple carbapenemases including metallo-beta-lactamases
• Without aztreonam, ceftazidime-avibactam alone will fail against MBL-producers 6

Critical Pitfalls to Avoid

1. Never use aminoglycoside monotherapy for serious infections—treatment failure and mortality are unacceptably high
2. Do not use tigecycline despite in vitro susceptibility—it is contraindicated for DFI with documented inferior outcomes 2
3. Do not delay surgical intervention while waiting for antibiotic response—source control is paramount 4
4. Do not ignore the possibility of heteroresistance—recent data shows 97% of K. pneumoniae isolates exhibit heteroresistance to at least one antibiotic, meaning resistant subpopulations exist even when susceptibility testing suggests sensitivity 9

If All Else Fails

If combination therapy with available agents fails and the infection is limb- or life-threatening:

• Consider amputation as definitive source control—preservation of life takes precedence over limb salvage
• Urgent infectious disease and surgical consultation for consideration of experimental or compassionate-use agents
• Re-culture to ensure the organism hasn't changed or developed additional resistance

The bottom line: Gentamicin or amikacin monotherapy is inadequate and potentially dangerous for this MDR diabetic foot infection. Combination therapy with aggressive surgical management is the only evidence-based approach that prioritizes patient survival and limb salvage.